Níveis de defeito do crescimento longitudinal ou linear;
O aumento da taxa de crescimento é mais significativo durante o 1º (primeiro) ano de tratamento com GH-hormônio de crescimento por DNA-recombinante. Criança, infantil, juvenil mais velha não responde com a mesma eficiência que crianças na fase mais adequada que é quando têm menos idade, nesta condição é necessário que se utilize doses maiores para um efeito mais adequado, principalmente quando a epífise óssea, embora aberta, possui certo avanço desproporcional com a idade cronológica. Doses mais altas, com até o dobro da dose inicial padronizada são aprovadas pelo FDA para o uso na puberdade, porém existem relatos variados acerca dos efeitos de doses tão altas sobre a estatura adulta, uma vez que o efeito principal do GH sobre a estatura de adulto ocorre nos anos antes da puberdade. O GH-hormônio de crescimento por DNA-recombinante não aumenta a taxa de crescimento linear ou longitudinal sem nutrição adequada e estatus eutireoidiano, ou seja, a tireóide tem que estar em perfeito funcionamento ou temos que corrigí-la concomitantemente com o tratamento de crescimento.
CONCLUSÃO: Com o diagnóstico e o tratamento estabelecido precocemente, usando-se os novos esquemas de doses puberais, a estatura longitudinal ou linear em adultos tratados na fase de crescimento corretamente, ou seja, fase criança-infantil-juvenil com GH-hormônio de crescimento por DNA-recombinante, a estatura adulta pode alcançar o potencial genético alvo.
HUMAN HEIGHT WITH LOW PITCH, INFANT, CHIL AND YOUTH RECEIVED GREAT GIFT IN 1986 TO CORRECT THOSE WHO HAD GH DEFICIENCY.
SPARE GH-GROWTH HORMONE BEFORE 1986 FOR CHILDREN, CHILD AND YOUTH, THE ONLY METHOD AVAILABLE FOR TREATMENT OF GH DEFICIENCY WAS A REPLACEMENT THERAPY WITH DONORS OF HUMAN HGH: PHYSIOLOGY-ENDOCRINOLOGY-NEUROENDOCRINOLOGY-GENETIC ENDOCRINE-PEDIATRICS (SUBDIVISION OF ENDOCRINOLOGY): DR. JOÃO SANTOS CAIO JR. ET DRA. HENRIQUETA VERLANGIERI CAIO.
Since 1985 the Creutzfeldt -JaKob disease, a rare degenerative neurological disease in such young patients as infant, child and youth, was diagnosed in some patients who had received hGH human. Due to the possibility of prions that infect the pituitary gland donor after death has been given to patients with DGH, causing impairment of their lives, the natural sources of human growth hormone GH-third removed from production and distribution the world market. The GH-growth hormone by recombinant DNA used as a revolutionary material, has 191 natural amino acids sequences. Currently, GH-growth hormone by DNA-recombinant facilitated the availability for those who have a precise indication of their use, which has not happened before because of the shortage of human donors and the limited employment which were used, e.g., in short stature, besides the effects with this new technology were banned in this therapy, reversing a substance as of the end of the XX century, but which was actually scheduled for the XXI century with an immense range of applications in all phases of age each day progresses with the development of scientific knowledge and new and unique directions for whom it is indicated. This significant discovery for children, kids, youth, teens and adults, has enabled previously impossible due to supply side effects and earlier innovative treatment regimens. Growth disorders due to disturbances of the release or action of GH-growth hormone are:
*Defect levels of the longitudinal or linear growth.
*Defect site Clinical Condition.
*Defective signal transduction of the growth hormone/JAK- STAT axis.
*Pygmies with normal GH, low IGF-I and normal concentrations of IGF-2.
© MMXI - VAN DER Haagen - ALL RIGHTS RESERVED 2014
The increased growth rate is most significant during the first (1st) year of growth by treatment with GH-growth hormone by DNA-recombinant. Children, infant, older juveniles do not respond with the same efficiency that children in the most appropriate stage younger, this condition is necessary to use higher doses for a better effect, especially when the bone although open epiphysis own right with disproportionate advancement chronological age. Higher dosages, up to twice the standard starting dose is approved by the FDA for use in puberty but there are various reports on the effects of such high doses to adult height, since the major effect of GH on stature occurs in adult years before puberty.
GH-growth hormone by DNA-recombinant does not increase the rate of linear or longitudinal growth without adequate nutrition and euthyroid status, e.g., the thyroid has to be in perfect working or have to correct it concurrently with the treatment of growth.
CONCLUSION: As established early diagnosis and treatment, using the new schemes pubertal doses, longitudinal or linear height in adults treated properly in the growth phase, e.g., child-juvenile phase with GH-growth hormone by DNA-recombinant adult stature can reach the genetic potential target.
Dr. João Santos Caio Jr.
Endocrinologia – Neuroendocrinologista
CRM 20611
Dra. Henriqueta V. Caio
Endocrinologista – Medicina Interna
CRM 28930
1. Este fator pode ser um benefício teórico no sentido do paciente que apresenta uma baixa estatura longitudinal ou linear significativa se comparado à idade cronológica e com a idade óssea defasada...
http://hormoniocrescimentoadultos.blogspot.com
2. Entretanto, temos que avaliar com bastante segurança o teste do GH que por outro lado pode nos confundir ocasionalmente com outra complicação interpretativa...
http://longevidadefutura.blogspot.com
3. Mesmo em uma faixa de normalidade, as variações do IMC afetam o pico de GH-hormônio de crescimento...
http://imcobesidade.blogspot.com
AUTORIZADO O USO DOS DIREITOS AUTORAIS COM CITAÇÃO
DOS AUTORES PROSPECTIVOS ET REFERÊNCIA BIBLIOGRÁFICA.
Referências Bibliográficas:
Caio Jr, João Santos, Dr.; Endocrinologista, Neuroendocrinologista, Caio,H. V., Dra. Endocrinologista, Medicina Interna – Van Der Häägen Brazil, São Paulo, Brasil; Wilson DM, Kripke DF, McClure DK, Greenburg AG: Ultradian cardiac rhythms in surgical intensive care unit patients. Psychosom Med 39:432-435, 1977; Wilson DM, Hopper AO, McDougall IR, Bayer MF, Hintz RL, Stevenson DK, Rosenfeld RG: Serum free thyroxine levels in term, premature and sick infants. J Pediatr 101:113-117, 1982; Wilson DM, Hintz RL: Interspecies comparison of somatomedin structure using immunological probes. J Endocrinol 95:59-64, 1982; Rosenfeld RG, Wilson DM, Dollar LA, Bennett A, Hintz RL: Both human pituitary growth hormone and recombinant DNA derived human growth hormone cause insulin resistance at a post-receptor level. J Clin Endocrinol Metab 54:1033-1038, 1982; Hintz RL, Rosenfeld RG, Wilson DM, Bennett A, Fenno J, McClellan B, Swift R: Biosynthetic methionyl-human growth hormone is biologically active in adult humans. Lancet 1:1276-1279,1982; Wilson DM, Bennett A, Adamson GD, Nagashima RJ, Liu F, DeNatale ML, Hintz RL, Rosenfeld RG: Somatomedins in pregnancy: A cross sectional study of insulin-like growth factors I and II and somatomedin peptide content in normal human pregnancies. J Clin Endocrinol Metab 56:858-861, 1982; Luna AM, Wilson DM, Wibbelsman CJ, Brown R, Nagashima RJ, Hintz RL, Rosenfeld RG: Somatomedins in adolescence: A cross sectional study of the effect of puberty on plasma insulin-like growth factors I and II levels. J Clin Endocrinol Metab 57:268-271, 1983; Bennett A, Wilson DM, Liu F, Nagashima RJ, Rosenfeld RG, Hintz RL: Levels of insulin-like growth factors I and II in cord blood of term infants. J Clin Endocrinol Metab 57:608-612, 1983; Wilson DM, Enzmann DR, Hintz RL, Rosenfeld RG: Cranial computed tomography in septo-optic dysplasia: Discordance of clinical and radiologic findings. Neuroradiology 26:279-283, 1984; Bryer-Ash M, Wilson DM, Tune BM, Rosenfeld RG, Shochat SJ, Luetscher JA: Hypertension due to aldosterone-producing adenoma in a seven year old girl: Case report and discussion of diagnostic approach. Am J Dis Child 138:673-676, 1984; Gertner JM, Genel M, Gianfredi SP, Hintz RL, Rosenfeld RG, Tamborlane WV, Wilson DM: Prospective clinical trial of human growth hormone in short children without growth hormone deficiency. J Pediatr 104:172-176, 1984; Rosenfeld RG, Ceda G, Wilson DM, Dollar LA, Hoffman AR: Characterization of high affinity receptors for insulin-like growth factors I and II on rat anterior pituitary cells. Endocrinology 114:1571-1575, 1984.
Contato:
Rua
Estela, 515 - Bloco D - 12º andar - Conj 121/122
Paraiso - São Paulo - SP - Cep 04011-002.
Paraiso - São Paulo - SP - Cep 04011-002.
Site Van Der Häägen Brazil
www.vanderhaagenbrazil.com.br
www.clinicavanderhaagen.com.br
www.crescimentoinfoco.com
www.obesidadeinfoco.com.br
http://drcaiojr.site.med.br
http://dracaio.site.med.br
João Santos Caio Jr
http://google.com/+JoaoSantosCaioJr
Vídeo
http://youtu.be/woonaiFJQwY
Google Maps:
http://maps.google.com.br/maps/place?cid=5099901339000351730&q=Van+Der+Haagen+Brasil&hl=pt&sll=-23.578256,46.645653&sspn=0.005074,0.009645&ie=UTF8&ll=-23.575591,-46.650481&spn=0,0&t = h&z=17